Trial Profile
Motion Sifnos: A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sickness
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 May 2020
Price :
$35
*
At a glance
- Drugs Tradipitant (Primary)
- Indications Motion sickness
- Focus Proof of concept; Therapeutic Use
- Acronyms Motion Sifnos
- Sponsors Vanda Pharmaceuticals
- 06 May 2020 According to a Vanda Pharmaceuticals media release, data from this study has been submitted to the peer-review publications.
- 09 Mar 2020 Status changed from recruiting to completed.
- 16 Jul 2019 Results published in the Vanda Pharmaceuticals media release